Valuation: Cogent Biosciences, Inc.

Market Cap 5.38B 4.82B 4.44B 4.02B 7.51B 511B 7.65B 52.89B 21.23B 269B 20.21B 19.78B 848B P/E 2026 *
-13.9x
P/E 2027 * -27.8x
Enterprise Value 5.25B 4.71B 4.33B 3.92B 7.33B 499B 7.47B 51.62B 20.72B 262B 19.72B 19.3B 828B EV / Sales 2026 *
877x
EV / Sales 2027 * 18.4x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-2.94%
1 week-0.61%
Current month-3.12%
1 month-3.12%
3 months-25.00%
6 months-13.33%
Current year-12.67%
1 week 30.52
Extreme 30.52
32.86
1 month 27.74
Extreme 27.735
32.86
Current year 27.74
Extreme 27.735
43.39
1 year 13.78
Extreme 13.78
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

759 0.0004%
27/08/26 Exercice

Director

136,530 0.0787%
01/07/26 Free

Director

627 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-2.94%-0.61%+91.36%+275.54% 5.38B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.01%+6.72%+52.21%+213.24% 39.97B
Weighted average by Cap. +0.14%+5.36%+49.08%+187.33%

Financials

2026 *2027 *
Net sales 5.99M 5.36M 4.93M 4.47M 8.36M 569M 8.51M 58.83M 23.62M 299M 22.47M 22M 943M 284M 254M 234M 212M 396M 26.94B 403M 2.79B 1.12B 14.17B 1.06B 1.04B 44.69B
Net income -395M -354M -326M -295M -552M -37.53B -562M -3.88B -1.56B -19.74B -1.48B -1.45B -62.27B -217M -194M -179M -162M -303M -20.6B -308M -2.13B -855M -10.83B -814M -797M -34.17B
Net Debt -130M -116M -107M -96.78M -181M -12.31B -184M -1.27B -511M -6.48B -487M -476M -20.42B -158M -142M -130M -118M -221M -15.01B -225M -1.55B -623M -7.9B -593M -581M -24.9B
Projected Income Statement - Annual - Cogent Biosciences, Inc.
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
30/10/26 $31.02 -2.94% 2,495,131
29/10/26 $31.96 -0.84% 1,515,523
28/10/26 $32.23 +0.69% 1,748,038
27/10/26 $32.01 +3.56% 1,838,365
26/10/26 $30.91 -0.96% 2,205,991
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Cogent Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
31.02USD
Average target price
55.82USD
Spread / Average Target
+79.94%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cogent Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. COGT Stock